How AI and new sources of high-quality data are redefining pharma’s approach to RWE
By synthesising RWE and AI, the industry can capitalise on the proliferation of data and unlock insights to drive the development and commercialisation of breakthrough medicines.
A snippet of learnings from JNJ, Bayer, Moderna, Novartis and more include:
- Synthetic data: learn how to leverage data that is modelled on RWD to navigate privacy concerns
- Social media: use online data to derive patient attitudes towards disease burdens and use this data to understand factors that prevent equal access to care
- Value of RWE: Win over payers and physicians by using RWE to showcase how your organization is enhancing clinical care
Please subscribe to view the analysis report